TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03762148

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ferrous fumarate
Description: nutritional iron (14 mg) supplement in form of ferrous fumarate

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ferrous sulphate
Description: nutritional iron (14 mg) supplement in form of ferrous sulphate

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ferric pyrophosphate
Description: nutritional iron (14 mg) supplement in form of ferric pyrophosphate

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ferrous fumarate + 3.5 g GOS
Description: nutritional iron (14 mg) supplement in form of ferrous fumarate with addition of prebiotics (3.5 g GOS)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ferrous fumarate + 7 g GOS
Description: nutritional iron (14 mg) supplement in form of ferrous fumarate with addition of prebiotics (7 g GOS)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ferrous sulphate + 15 g GOS
Description: nutritional iron (14 mg) supplement in form of ferrous sulphate with addition of prebiotics (15 g GOS)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ferrous fumarate + Vitamin C
Description: nutritional iron (14 mg) supplement in form of ferrous fumarate with addition of Vitamin C

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ferric pyrophosphate + 15 g GOS
Description: nutritional iron (14 mg) supplement in form of ferric pyrophosphate with addition of prebiotics (15 g GOS)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ferrous fumarate + 7 g GOS + Vitamin C
Description: nutritional iron (14 mg) supplement in form of ferrous fumarate with addition of prebiotics (7 g GOS) and Vitamin C
Study: NCT03994692

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PEEK eminoplasty
Description: making obstacle at eminence using patient specefic PEEK device
Study: NCT02843100

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Partial Enteral Nutrition
Description: 25-50% of Energy from formula

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Exclusive Enteral Nutrition
Description: 8 weeks of Exclusive Enteral Nutrition
Study: NCT03434600

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oxford UKA vs Sigma UKA

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oxford UKA vs Sigma UKA
Study: NCT03994692

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: autogenous onlay grafting eminoplasty
Description: making obstacle at eminence using chin graft
Study: NCT00415233

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant thyroid-stimulating hormone
Description: Recombinant thyroid stimulating hormone (rhTSH) should be given at a dose of 0.9mg by intramuscular injection on two consecutive days before ablation.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant thyroid-stimulating hormone
Description: Recombinant thyroid stimulating hormone (rhTSH) should be given at a dose of 0.9mg by intramuscular injection on two consecutive days before ablation.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiodine ablation without rhTSH
Description: Patients in this group do not receive rhTSH pre ablation.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiodine ablation without rhTSH
Description: Patients in this group do not receive rhTSH pre ablation.
Study: NCT01909596

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Neutral customized foot orthoses
Description: Foot orthoses with arch support and without lateral inclination

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 6° lateral customized foot orthoses
Description: Foot orthoses with arch support above insoles with lateral inclination set at 6°

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 10° lateral customized foot orthoses
Description: Foot orthoses with arch support above insoles with lateral inclination set at 10°
Study: NCT00451321

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Otelixizumab
Description: Infusion
Study: NCT03559946

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: percutaneous tibial nerve stimulation (PTNS)
Description: The PTNS and the sham treatments will be given in 30 min sessions. The PTNS treatment consists of inserting a 34-gauge needle electrode approximately 5 cm cephalad to the medial malleolus and, as well as placing a PTNS surface electrode on the ipsilateral calcaneus. To keep the electrode placement consistent with the sham treatment, 2 inactive transcutaneous electrical nerve stimulation (TENS) surface electrodes are also added, 1 placed under the little toe and 1 on the top of the foot. The PTNS lead set is connected to the Urgent PC stimulator, and a current level of 0.5 to 10 mA at 20 Hz is delivered until the flexion of the big toe is observed or the patient reports a radiating sensation at the sole of the foot.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: percutaneous tibial nerve stimulation (PTNS)
Description: The PTNS and the sham treatments will be given in 30 min sessions. The PTNS treatment consists of inserting a 34-gauge needle electrode approximately 5 cm cephalad to the medial malleolus and, as well as placing a PTNS surface electrode on the ipsilateral calcaneus. To keep the electrode placement consistent with the sham treatment, 2 inactive transcutaneous electrical nerve stimulation (TENS) surface electrodes are also added, 1 placed under the little toe and 1 on the top of the foot. The PTNS lead set is connected to the Urgent PC stimulator, and a current level of 0.5 to 10 mA at 20 Hz is delivered until the flexion of the big toe is observed or the patient reports a radiating sensation at the sole of the foot.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham procedure
Description: The sham treatment, involves simulating the sensation of the PTNS needle insertion at the same location using a Steritberger placebo needle. This is a blunt tip needle which simulates the sensation of a needle prick when touched to the skin, however, the blunt tip retracts into the handle when pressed into the skin. This creates the illusion of the needle entering the skin, without breaking the skin's surface. An inactive PTNS surface electrode is also placed on the ipsilateral calcaneus. The two TENS surface electrodes, placed in the same location as the PTNS treatment, are active and deliver stimulation mimicking the sensory effects of the PTNS. However, since no electrode needles were inserted near the tibial nerve, there will be no tibial nerve stimulation
Study: NCT02064166

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal Insulin
Description: 1. treatment arm: Insulin, 40 international units daily, intranasally, for 4 weeks;~2. placebo arm: normal saline, daily, intranasally, for 4 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intranasal Insulin
Description: 1. treatment arm: Insulin, 40 international units daily, intranasally, for 4 weeks;~2. placebo arm: normal saline, daily, intranasally, for 4 weeks.
Study: NCT02083731

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MSCs
Study: NCT01424254

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Capsule GIVEN IMAGING
Description: Injection of Capsule Endoscopy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Push-Enteroscopy
Description: currently recommended standard
Study: NCT01627821

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Jarvik 2000 VAS
Description: Jarvik 2000 LVAD

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HeartMate II
Description: HeartMate II LVAD
Study: NCT02167607

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator
Description: Purple Potato

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Placebo Comparator
Study: NCT02208856

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBR 796 BS

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBR 796 BS

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high fat standardized breakfast
Study: NCT02662127

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SIGVARIS® Class 2 - RAL: 23-32.
Description: Below knee graduated elastic compression stocking
Study: NCT05451147

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chhinnavahni Kashaya Vati along with Agnimantha Kwatha
Description: Drug: Chhinnavahni Kashaya Vati Form : Tablet Dose: 1g TDS (2x500 mg), Before meals Mode of Administration: Oral Anupaan: 20 ml of Agnimantha Kwatha Duration: 3 Months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin Hydrochloride
Description: Drug: Metformin Form: Tablet Dose: 500mg BID/TDS, Before meals Mode of Administration: Oral Anupaan: Plain water Duration: 3 Months
Study: NCT01661192

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AAT( Alpha 1 Antitrypsin)
Study: NCT03192592

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Body moisturizer
Description: Daily body moisturizer application for skin protection and barrier.
Study: NCT04147455

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adapted RealConsent
Description: The program is a novel, theory-driven, evidence-based serial drama and educational program tailored to young men and delivered in six episodes via the web. Participants will view six 30-minute modules designed to prevent sexual violence in young men

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education Control Condition
Description: Participants will view six 30-minute web-based serial drama modules designed to promote health.
Study: NCT04339296

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spencer
Description: The MDS dispenses medications on time with visual and audio reminders. The audio alert get louder if the plastic medication packet is not dispensed from the system. The MDS allows participants to dispense their medications early if they are going to be away from home. The system also displays personalized and health-condition speciﬁc questions. The pre-packaged medications are delivered by pharmacy that inserted directly into the spencer device. Spencer system is non-inclusive and approved by Health Canada.
Study: NCT00003389

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Study: NCT00784316

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metoprolol, amiodarone
Description: to compare the effectiviness of intravenous administration of metoprolol and amiodarone in the prevention of atrial fibrillation after cardiac surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metoprolol, amiodarone
Description: to compare the effectiviness of intravenous administration of metoprolol and amiodarone in the prevention of atrial fibrillation after cardiac surgery
Study: NCT00863434

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clofarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given SC
Study: NCT05262946

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: sensorimotor training based on Feldenkrais method
Description: 8 weeks of balance and sensorimotor training twice a week

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: foot care education
Description: Recommendations for preventing foot ulcers

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: foot care education
Description: Recommendations for preventing foot ulcers

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: usual care
Description: drugs and diet usual care

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: usual care
Description: drugs and diet usual care
Study: NCT00002624

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adjuvant therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: diagnostic thoracoscopy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic thoracoscopy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: video-assisted surgery

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study: NCT00888992

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quitline Service + 10 automated monitoring calls
Description: This group will receive the usual care provided in Alere Wellbeing's Quit For Life® program. The program includes 5 telephone counseling calls. In addition, participants receive 10 automated telephone monitoring calls to help them stay off cigarettes. The automated call schedule will be two calls per a week for 2 weeks, then once a week for 6 weeks. Participants whose answers indicate that they may be having trouble quitting smoking will be automatically connected to a Quit Coach for individualized relapse prevention counseling.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quitline service + 20 automated monitoring calls
Description: This group will receive the usual care provided in Alere Wellbeing's Quit For Life® program. The program includes 5 telephone counseling calls. In addition, participants receive 20 automated telephone monitoring calls to help them stay off cigarettes. The automated call schedule will be one automated call a day for 2 weeks, then once a week for 6 weeks. Participants whose answers indicate that they may be having trouble quitting smoking will be automatically connected to a Quit Coach for individualized relapse prevention counseling.
Study: NCT01797042

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dietary Compliance
Description: Incorporation of sugar sweetened milk into the usual diet. Instruction on how to account for additional calories provided by sugar sweetened milk Weekly compliance checks

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dietary Compliance
Description: Incorporation of sugar sweetened milk into the usual diet. Instruction on how to account for additional calories provided by sugar sweetened milk Weekly compliance checks

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dietary Compliance
Description: Incorporation of sugar sweetened milk into the usual diet. Instruction on how to account for additional calories provided by sugar sweetened milk Weekly compliance checks

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dietary Compliance
Description: Incorporation of sugar sweetened milk into the usual diet. Instruction on how to account for additional calories provided by sugar sweetened milk Weekly compliance checks
Study: NCT04568382

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CI-PVP (context-informed pre-visit planning)
Description: may experience a single additional phone call from clinic staff in addition to the standard clinic staff chart review, email and/or phone call prior to diabetes office visit

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard PVP (pre-visit planning)
Description: standard clinic staff chart review, email and/or phone call prior to diabetes office visit
Study: NCT01547494

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vegan Diet
Description: Vegan diet, which is devoid of animal products and minimal in fat

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: mixture of omega3 and vitamins
Description: mixture of omega3 and vitamins
Study: NCT01509066

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diet
Description: Dietary approaches for PCOS

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet
Description: Dietary approaches for PCOS
Study: NCT01174602

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure Therapy for AN (AN-EX/RP)
Description: 12 Sessions, 3 times per week. 90 minute sessions. Group therapy twice per week.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Remediation Therapy
Description: 12 Sessions, 3 times per week. 45 minute sessions. Group therapy twice per week.
Study: NCT01294761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir, Darunavir/r
Description: An arm to change the regimen to: raltegravir and darunavir/ritonavir~Prezista naive 2 tabs PC QD, Norvir soft-capsule 1 cap PC QD and Isentress 1 tab BID or Prezista 2 tabs PC BID and Norvir soft-capsule 1 cap PC BID, and Isentress 1 tab BID~from: Kaletra 4 tabs QD and Truvada 1 tab QD or Kaletra 4 tabs QD, Viread 1 tab QD, Epivir300mg 1 tab (or Epivir 150mg 2 tabs) QD
Study: NCT03799133

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Florence device
Description: The Florence catheter will be placed at the beginning of the surgery and up to 72 hours in ICU.
Study: NCT01908335

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-IFN-SA /RBV low dose
Description: 24 weeks for genotype 2,3 and 48 weeks for non-genotype2,3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-IFN-SA /RBV middle dose
Description: 24 weeks for genotype 2,3 and 48 weeks for non-genotype2,3
Study: NCT01499979

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: In situ hypothermic perfusion
Description: In situ perfusion of the future remnant liver with chilled lactated Ringer's solution during liver resection.
Study: NCT03111706

Intervention type: PROCEDURE
Intervention: Cesarean section
Description: During Cesarean delivery the lower uterine segment (LUS) was defined as the part of the uterus below the uterovesical peritoneal reflection. After opening the visceral peritoneum and performing the bladder dissection, the LUS was assessed for integrity of the CS scar by the operating surgeon to avoid bias by the sonographic findings. Scar dehiscence was defined as the presence of either transparent LUS with visible contents, presence of well-circumscribed scar defect or presence of frank uterine rupture.

Intervention type: PROCEDURE
Intervention: Cesarean section
Description: During Cesarean delivery the lower uterine segment (LUS) was defined as the part of the uterus below the uterovesical peritoneal reflection. After opening the visceral peritoneum and performing the bladder dissection, the LUS was assessed for integrity of the CS scar by the operating surgeon to avoid bias by the sonographic findings. Scar dehiscence was defined as the presence of either transparent LUS with visible contents, presence of well-circumscribed scar defect or presence of frank uterine rupture.
Study: NCT01014559

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone Naloxone
Description: Oxycodone Naloxone PR Tablet taken twice daily
Study: NCT04124289

Intervention type: OTHER
Intervention: Pain measurement using 3 scales
Description: Patients will assess their pain after surgery using three different pain scales.
Study: NCT02089659

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doravirine
Description: Following an overnight fast, a single tablet of 100 mg doravirine was be administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doravirine
Description: Following an overnight fast, a single tablet of 100 mg doravirine was be administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doravirine
Description: Following an overnight fast, a single tablet of 100 mg doravirine was be administered orally
Study: NCT00194779

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinorelbine tartrate
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: needle biopsy
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Undergo definitive breast surgery

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tamoxifen citrate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: letrozole
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT02128321

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isavuconazole
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Repaglinide
Description: oral
Study: NCT01014559

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone PR Tablets
Description: Oxycodone PR Tablets taken twice daily
Study: NCT03977805

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hetrombopag Olamine
Description: a single oral taking
Study: NCT02813174

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Compassionate Mind Training from Compassion-Focused Therapy